Delivery Order SPE2DB20D3505-SPE2DB24FT2W4
- Not listed
- This federal contract award is for the delivery of WEGOVY 1.7 mg/0.75 ml pens to the Defense Logistics Agency (DLA). The contract, valued at $2,522.11, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 13, 2024 and is a firm fixed-price delivery order. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery...
- This federal contract award is for the delivery of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a delivery order contract with a firm fixed price of $2,026.06 and a completion date of February 20, 2024. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp is the prime contractor on an Indefinite Delivery...
- This federal contract award is for the delivery of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $4,020.42 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of July 16, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is for the delivery of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML medication to the Defense Logistics Agency (DLA). The $6,033.94 firm fixed price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a completion date of July 27, 2023 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award is for the delivery of WEGOVY 1 MG/0.5 ML PEN 0.5ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $2,770.74 firm fixed-price contract was awarded to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 6, 2024 and was awarded on November 5, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite...
- This federal contract award is for the delivery of WEGOVY 1 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of January 11, 2024 and a ceiling value of $1,967.86. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. This award is not designated as a set-aside. Amerisourcebergen Drug Corp...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4564306670 - WEGOVY 1 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has a ceiling value of $1,097.08 and an ultimate completion date of April 18, 2024. Amerisourcebergen Drug Corp's Corporate Office Division holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00...
- This federal contract award is for the delivery of WEGOVY 1 MG/0.5 ML PEN 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $4,310.09 firm fixed-price delivery order was competitively awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, and does not have a set-aside designation. The contract has an ultimate completion date of July 18, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
- This federal contract award is for the delivery of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $13,701.30 fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of February 18, 2025 and is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- The federal contract award is for the delivery of WEGOVY 1 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,097.08, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. This is a delivery order contract with a firm fixed price. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB24FT2W4Delivery Order
This federal contract award is for the delivery of WEGOVY 1 MG/0.5 ML PEN 0.5ML to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,150.31 and a completion date of October 25, 2023. It is a delivery order contract with a firm fixed price pricing type. The contract is not set aside for any specific business type. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which is the parent company. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 10/24/23 |